Biomarkers associated with severe hypoglycaemia and death in ACCORD

Diabetic Medicine

Volumn 33, Issue 8, 2016, Pages 1076-1083

  Chow, L S ^a   Chen, H ^b   Miller, M E ^b   Marcovina, S M ^c   Seaquist, E R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C PEPTIDE; GLUTAMATE DECARBOXYLASE; INSULIN; TYROSINE PHOSPHATASE RELATED ISLET ANTIGEN 2; UNCLASSIFIED DRUG; ZINC TRANSPORTER;

AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEFICIENCY; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERSONAL EXPERIENCE; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN;

EID: 84978859567     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12883     Document Type: Article

References (30)

1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–1589.
2. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in Type 2 diabetes. N Engl J Med 2008; 358: 2545–2559.
3. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD et al. Glucose control and vascular complications in veterans with Type 2 diabetes. N Engl J Med 2009; 360: 129–139.
4. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N Engl J Med 2008; 358: 2560–2572.
5. Miller ME, Bonds DE, Gerstein HC, Seaquist ER, Bergenstal RM, Calles-Escandon J et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010; 340: b5444.
6. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363: 1410–1418.
7. Cryer PE. Severe hypoglycemia predicts mortality in diabetes. Diabetes Care 2012; 35: 1814–1816.
8. Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 2002; 51: 724–733.
9. Gottsater A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 1993; 16: 902–910.
10. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993; 42: 359–362.
11. Gavin JR, Alberti K, Davidson MB, DeFronzo RA, Drash A, Gabbe SG et al. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2000; 23: S4–S19.
12. Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99: 21i–33i.
13. The ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818–828.
14. Bergstralh EJ, Kosanke JL, Jacobsen SJ. Software for optimal matching in observational studies. Epidemiology (Cambridge, Mass) 1996; 7: 331–332.
15. Berger B, Stenstrom G, Sundkvist G. Random C–peptide in the classification of diabetes. Scand J Clin Lab Invest 2000; 60: 687–693.
16. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 1993; 16: 155–165.
17. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001; 161: 1653–1659.
18. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010; 340: b4909.
19. McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 2012; 35: 1897–1901.
20. Chow LS, Chen H, Miller ME, Marcovina SM, Seaquist ER. Biomarkers related to severe hypoglycaemia and lack of good glycaemic control in ACCORD. Diabetologia 2015; 58: 1160–1166.
21. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007; 50: 1140–1147.
22. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003; 26: 1902–1912.
23. Struthers AD, Reid JL, Whitesmith R, Rodger JC. The effects of cardioselective and non-selective beta-adrenoceptor blockade on the hypokalaemic and cardiovascular responses to adrenomedullary hormones in man. Clin Sci (Lond) 1983; 65: 143–147.
24. Lee S, Harris ND, Robinson RT, Yeoh L, Macdonald IA, Heller SR. Effects of adrenaline and potassium on QTc interval and QT dispersion in man. Eur J Clin Invest 2003; 33: 93–98.
25. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003; 26: 1485–1489.
26. Chow E, Bernjak A, Williams S, Fawdry RA, Hibbert S, Freeman J et al. Risk of cardiac arrhythmias during hypoglycemia in patients with Type 2 diabetes and cardiovascular risk. Diabetes 2014; 63: 1738–1747.
27. Irvine WJ, Gray RS, McCallum CJ, Duncan LJP. Clinical and pathogenic significance of pancreatic–islet-cell antibodies in diabetics treated with oral hypoglycaemic agents. Lancet 1977; 1: 1025–1027.
28. Zimmet PZ. The pathogenesis and prevention of diabetes in adults. Genes, autoimmunity, and demography. Diabetes Care 1995; 18: 1050–1064.
29. Myhill P, Davis WA, Bruce DG, Mackay IR, Zimmet P, Davis TM. Chronic complications and mortality in community-based patients with latent autoimmune diabetes in adults: the Fremantle Diabetes Study. Diabet Med 2008; 25: 1245–1250.
30. Seaquist ER, Chen H, Marcovina S, Miller M, Chow LS. Baseline insulin deficiency is associated with increased mortality and severe hypoglycaemia in the ACCORD study. Diabetes 2014; 63(Suppl 2): 393.